ICMR-Regional Medical Research Centre, Chandrasekharpur, Bhubaneswar751023, Odisha, India.
Epidemiol Infect. 2022 Mar 3;150:e58. doi: 10.1017/S0950268822000346.
COVID-19 serosurvey provides a better estimation of people who have developed antibody against the infection. But limited information on such serosurveys in rural areas poses many hurdles to understand the epidemiology of the virus and to implement proper control strategies. This study was carried out in the rural catchment area of Model Rural Health Research Unit in Odisha, India during March-April 2021, the initial phase of COVID vaccination. A total of 60 village clusters from four study blocks were identified using probability proportionate to size sampling. From each cluster, 60 households and one eligible participant from each household (60 per cluster) were selected for the collection of blood sample and socio-demographic data. The presence of SARS-CoV-2 antibody was tested using the Elecsys Anti-SARS-CoV-2 immunoassay. The overall seroprevalence after adjusting for test performance was 54.21% with an infection to case ratio of 96.89 along with 4.25% partial and 6.79% full immunisation coverage. Highest seroprevalence was observed in the age group of 19-44 years and females had both higher seroprevalence as well as vaccine coverage. People of other backward caste also had higher seropositivity than other caste categories. The study emphasises on continuing surveillance for COVID-19 cases and prioritizing COVID-19 vaccination for susceptible groups for better disease management.
COVID-19 血清学调查提供了对感染产生抗体的人群的更好估计。但是,农村地区此类血清学调查的信息有限,这给了解病毒的流行病学和实施适当的控制策略带来了许多障碍。本研究于 2021 年 3 月至 4 月在印度奥里萨邦的农村 Model Rural Health Research Unit 进行,这是 COVID 疫苗接种的初始阶段。使用比例概率抽样方法确定了来自四个研究区的 60 个村庄集群。从每个集群中,选择 60 户家庭和每个家庭的一名合格参与者(每个集群 60 人),以采集血液样本和社会人口学数据。使用 Elecsys Anti-SARS-CoV-2 免疫分析检测 SARS-CoV-2 抗体的存在。在调整了测试性能后,总血清阳性率为 54.21%,感染与病例比为 96.89%,部分免疫接种率为 4.25%,完全免疫接种率为 6.79%。在 19-44 岁年龄组中观察到最高的血清阳性率,女性的血清阳性率和疫苗接种率均较高。其他落后种姓的人也比其他种姓类别的人具有更高的血清阳性率。该研究强调继续对 COVID-19 病例进行监测,并为易感人群优先接种 COVID-19 疫苗,以更好地进行疾病管理。